Originally developed by Celgene ahead of its $74 billion takeover by BMS, Zeposia has been trumpeted as one of the top 2020 drug launches to watch by Clarivate, which expects sales to reach $1.6 ...

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

Zeposia has been developed for adult patients with relapsing remitting MS, where the patient has flare-ups followed by periods of remission. It is a treatment option which may reduce the need to ...